The stock of Neumora Therapeutics Inc (NASDAQ: NMRA) has decreased by -8.57 when compared to last closing price of 1.40.Despite this, the company has seen a loss of -14.09% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-16 that NEW YORK, NY / ACCESS Newswire / March 16, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=136420&wire=1 or contact Joseph E. Levi, Esq.
Is It Worth Investing in Neumora Therapeutics Inc (NASDAQ: NMRA) Right Now?
NMRA has 36-month beta value of 1.96. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for NMRA is 56.00M, and currently, short sellers hold a 21.93% ratio of that float. The average trading volume of NMRA on March 17, 2025 was 3.29M shares.
NMRA’s Market Performance
NMRA stock saw a decrease of -14.09% in the past week, with a monthly decline of -24.71% and a quarterly a decrease of -87.68%. The volatility ratio for the week is 10.28%, and the volatility levels for the last 30 days are 8.60% for Neumora Therapeutics Inc (NMRA). The simple moving average for the last 20 days is -16.95% for NMRA’s stock, with a simple moving average of -85.97% for the last 200 days.
Analysts’ Opinion of NMRA
Stifel, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $2, previously predicting the price at $6. The rating they have provided for NMRA stocks is “Hold” according to the report published on March 07th, 2025.
NMRA Trading at -36.58% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.55% of loss for the given period.
Volatility was left at 8.60%, however, over the last 30 days, the volatility rate increased by 10.28%, as shares sank -24.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -88.43% lower at present.
During the last 5 trading sessions, NMRA fell by -14.09%, which changed the moving average for the period of 200-days by -86.04% in comparison to the 20-day moving average, which settled at $1.5410. In addition, Neumora Therapeutics Inc saw -87.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Henry Gosebruch, who proposed sale 15,000 shares at the price of $1.43 back on Mar 12 ’25. After this action, Henry Gosebruch now owns shares of Neumora Therapeutics Inc, valued at $21,450 using the latest closing price.
BERNS PAUL L, the of Neumora Therapeutics Inc, sale 13,871 shares at $1.69 during a trade that took place back on Feb 18 ’25, which means that BERNS PAUL L is holding 7,405,004 shares at $23,468 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.92. Equity return is now at value -64.48, with -59.96 for asset returns.
Based on Neumora Therapeutics Inc (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -98.72.
Currently, EBITDA for the company is -263.46 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.51.
Conclusion
To put it simply, Neumora Therapeutics Inc (NMRA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
